The exact functions of BRCA1 have not been fully described but it now seems apparent that it has roles in DNA damage repair, transcriptional regulation, cell cycle control and most recently in ubiquitylation. These functions of BRCA1 are most likely interdependent but this review will focus on the role of BRCA1 in relation to transcriptional regulation and in particular how this impacts upon cell cycle control. We will (i) describe the structure of BRCA1 and how it may contribute to its transcription function; (ii) describe the interaction of BRCA1 with the core transcriptional machinery (RNA polII); (iii) describe how BRCA1 may regulate transcription at an epigenetic level through chromatin modification; (iv) discuss the role of BRCA1 in modulating transcription through its association with sequence-specific transcription factors. Finally, we will discuss the possible effects of BRCA1 transcriptional regulation on downstream targets with known roles in cell cycle control.
Introduction
BRCA1 was the first breast and ovarian cancer susceptibility gene to be identified by linkage analysis of families with multiple cases of early onset breast and ovarian cancer (Miki et al., 1994) . Human BRCA1 encodes an 1863 amino-acid (aa) protein which has been shown to be a predominantly nuclear protein (Chen et al., 1996) . It has three main features thought to be important for function, namely an amino-terminal RING finger domain, a pair of nuclear localization signals (NLSs) in the central region of the molecule and a pair of BRCA1 C-terminal (BRCT) domains. The RING finger domain is thought to be important for its association with a number of proteins, in particular BRCA1-associated ring domain 1 (BARD1), and BRCA1-BARD1 heterodimers have been shown to act as ubiquitin ligases (Wu et al., 1996; Hashizume et al., 2001) . The presence of the NLSs is consistent with BRCA1 being a predominantly nuclear protein. Finally, the BRCT domains (aa 1653-1736 and 1760-1855) were first identified in BRCA1 but have now been shown to be present in an ever expanding group of proteins whose common functions are in DNA damage repair and cell cycle control (Bork et al., 1997) . The BRCA1 protein has been shown to tolerate truncations of up to eight aa from its carboxy-terminus (C-terminal), but further deletion results in drastic BRCT folding defects as shown by proteolytic methods and computational predictive methods (Williams and Glover, 2003) . BRCT domains have now been postulated to be phosphopeptide-binding motifs with high affinity for phosphoserine and phosphothreonine residues (Manke et al., 2003) .
BRCA1 and transcriptional regulation
BRCA1 structure/function analysis The structure of the BRCA1 protein gave the first clues that it might play a role in transcriptional regulation. While BRCA1 has very limited homology to any other known proteins a role for BRCA1 in transcription was predicted given the high content of negatively charged aa in the C-terminus of the molecule (Miki et al., 1994) . Experiments using the C-terminus of BRCA1 (aa 1560-1863) fused to a GAL4 DNA-binding domain (BRCA1-GAL4) showed that BRCA1 could activate transcription in both yeast and mammalian cells (Monteiro et al., 1996) . Furthermore, germline point mutations of this C-terminal region found in patients with early onset breast or ovarian cancer were deficient in transcriptional activation, suggesting that the ability of BRCA1 to regulate transcription was key to its tumor suppressor activity (Monteiro et al., 1996) . The importance of this region of BRCA1 to transcriptional control and growth suppression is also highlighted by the fact that cancerassociated mutations abrogated both while neutral polymorphisms did not (Humphrey et al., 1997) . Transcriptional activation by GAL4-BRCA1 fusions was found to be optimal in the presence of certain cofactors and also differed significantly from the standard activator GAL4-VP16 in terms of DNA topology and TFIIH concentrations (Haile and Parvin, 1999) .
BRCA1 and RNA polymerase II For a number of years there has been a growing body of evidence to support a role for BRCA1 in transcriptional regulation. BRCA1 copurifies with the RNA polymerase II (RNA polII) holoenzyme complex through an association with RNA helicase A (Anderson et al., 1998) , suggesting that BRCA1 is a component of the core transcriptional machinery. Indeed, BRCA1 could be copurified with RNA polII, whereas a number of other transcription factors could not under identical conditions (Scully et al., 1997) . The link between the role of BRCA1 in transcription and tumor suppression was demonstrated further by the fact that cancer-associated point mutations of BRCA1 were found to disrupt the BRCA1-polII interaction (Scully et al., 1997) . RNA helicase A is known to interact with the transcriptional coactivator p300/CBP (Anderson et al., 1998) and BRCA1 also interacts with p300/CBP but these associations appear to involve different regions of the p300/ CBP molecule (Pao et al., 2000) . As well as interacting with RNA polII and regulating transcriptional activation, BRCA1 has been shown to modulate the phosphorylation status of the C-terminal domain (CTD) of RNA polII, negatively regulating phosphorylation by the Cdk-activating kinase (CAK) (Moisan et al., 2004) . This negative regulatory activity was shown to be due to the C-terminus of BRCA1 and its function is yet to be elucidated but suggests that BRCA1 through regulation of CAK may control cell cycle or enhance NER/TCR at the sites of DNA damage (Moisan et al., 2004) .
RNA polII may also be a target for BRCA1/BARD1 ubiquitin ligase activity following DNA damage (Hashizume et al., 2001 ). In such a scenario, RNA polII and the coupled 3 0 -RNA processing machinery stalled at the sites of DNA damage may be targeted by BRCA1/ BARD1 for degradation, permitting access for repair machinery (Kleiman et al., 2005) . Deletions of the BRCA1 amino-terminus (which associates with BARD1 and a number of other proteins) abrogates the ability of BRCA1 to interact with the RNA polII holoenzyme as well as the localization of BRCA1 in S-phase foci (Chiba and Parvin, 2002) . BRCA1 is thought to specifically target Rpb1 (the largest subunit of RNA polII) for ubiquitylation, an event which was dependent on phosphorylation of Rpb1 on a specific serine (serine 5 of the C-terminal heptad repeat YSPTSPS) (Starita et al., 2005) . This residue is phosphorylated by Cdk7 (a subunit of TFIIH) and this is followed by phosphorylation of serine 2 of this heptad repeat by Cdk9/pTEFb. There are 52 repeats of this heptad in RNA polII CTD and multiple phosphorylations are required to generate the hyperphosphorylated RNA polII form associated with elongation. The association of hypophosphorylated BRCA1 with preferentially the hyperphosphorylated (postinitiation) form of RNA polII suggests that BRCA1 does not affect direct promoter activation but plays roles in transcription related to chromatin remodeling as well as transcription-coupled repair (Krum et al., 2003) .
BRCA1 was also shown by yeast two-hybrid to associate with the zinc-finger containing nuclear protein NUFIP (Cabart et al., 2004) . NUFIP stimulates activator-independent transcription by RNA polII both in vitro and in vivo and associates with preinitiation, open transcription and elongation complexes and facilitates the ATP-dependent dissociation of hyperphosphorylated RNA polII from open transcription complexes (Cabart et al., 2004) . NUFIP also interacts with the positive elongation factor pTEFb, placing BRCA1 in a complex with other proteins involved in mRNA elongation (Cabart et al., 2004) . BRCA1 may therefore utilize its association with RNA polII to stimulate mRNA transcription while simultaneously monitoring the fidelity of DNA removing RNA polII from actively transcribing genes upon encountering damaged DNA.
BRCA1 and chromatin remodeling
The retinoblastoma suppressor (Rb-) associated protein (RbAp46) (Chen et al., 2001) , which is also a growth suppressor, was identified by a yeast two-hybrid assay to interact with and alter the transcriptional activity of BRCA1. RbAp46 is a component of the histone modifying and remodeling complexes and inhibits transactivation by a BRCA1-GAL4 fusion protein as well as activation of a p21 cip1/WAF1 promoter construct (Ahmad et al., 2000) . The function of this interaction is unknown but it is disrupted by DNA damage so RbAp46 may act to sequester BRCA1 in the absence of DNA damage. The BRCT domain of BRCA1 was also found to interact with another Rb-associated protein, RbAp48, as well as Rb itself (Yarden and Brody, 1999) . The ability of BRCA1 to act as either a coactivator or corepressor of transcription may involve its ability to recruit both the basal transcription machinery (through RNA polII interaction), proteins implicated in chromatin remodeling, such as the histone deacetylases HDAC1 and HDAC2 (Yarden and Brody, 1999) or components of the SWI/SNF-related chromatin-remodeling complex (Bochar et al., 2000) . BRCA1 interacts directly with the BRG1 subunit of the SWI/ SNF complex and an exon 11 deletion mutant of BRCA1 or a dominant-negative mutation of BRG1 resulted in loss of p53-mediated stimulation of transcription by BRCA1 (Bochar et al., 2000) . SWI/SNF enzymes are recruited to sites of transcriptional activation in a transcription factor-dependent manner and the DNA-binding domains of several zinc-finger proteins are known to interact with SWI/SNF enzymes to target chromatin remodeling to specific promoters. Interestingly, remodeling can be achieved with only the BRG1-BAF155 minimal complex, whereas transcription requires the presence of an activation domain (Kadam et al., 2000) . In this context, BRCA1 may function to provide the activation function in collaboration with sequence-specific transcription factors such as p53.
There are a number of other reports linking BRCA1 and chromatin remodeling. Targeting BRCA1 to an amplified region on a mammalian chromosome resulted in localized chromatin decondensation, an activity which was conferred by both BRCT domains and an activation domain (AD1) on BRCA1 (Ye et al., 2001) . BRCA1 has been shown to interact with hGCN5 and TRRAP in a histone acetyltransferase (HAT) complex which required the presence of wild-type BRCA1 for transcriptional activation (Oishi et al., 2006) . Cancerassociated germline mutations in the C-terminus of BRCA1 abolished these interactions and transcriptional activation (Oishi et al., 2006) .
As already noted, BRCA1 has also been shown to physically interact with the paralogous HATs p300 and CBP (Pao et al., 2000) . Both the amino-and C-terminal of BRCA1 have been shown to interact with p300/CBP and the transcriptional activation activity of BRCA1 was shown to be further enhanced by p300/CBP (Bernabei et al., 2003) . HATs are important for the optimal transcriptional activity of many transcription factors since they acetylate the amino-terminal lysine residues of core histones to reduce their positive charge and thus reducing their binding affinity for DNA. In addition, CBP and p300 are able to interact with a host of other HATs such as P/CAF and ACTR/SRC-1. The association of BRCA1 with p300/CBP (and of both proteins with RNA helicase A) would therefore bring BRCA1 into close proximity with both the core transcriptional machinery as well as a large complex of chromatin remodeling proteins to facilitate optimal transactivation.
Interaction of BRCA1 with known transcription factors
Estrogen receptor-a Given that factors which contribute to enhanced exposure to estrogen, such as early onset of menarche, nulliparity or late menopause all correlate with the incidence of breast cancer (Hulka and Moorman, 2001) , the association between BRCA1 and estrogen receptor-a (ER)-a represents a potentially important growth regulatory mechanism in breast biology. Most ER-aassociated molecules participate in the modification of chromatin structure or in the recruitment of the regulatory complexes at the level of transcription initiation. BRCA1 is known to mediate ligand-independent transcriptional repression by ER-a (Zheng et al., 2001) . Consistent with this observation, when the function of BRCA1 is abrogated such as in Brca1-null mouse embryonic fibroblasts or BRCA1-deficient ovarian cells, ER-a exhibited ligand-independent transcriptional activity not observed in BRCA1 proficient cells (Zheng et al., 2001) . BRCA1 was associated with ER-a before, but not after estrogen stimulation as shown by chromatin immunoprecipitation experiments suggesting that BRCA1 acts as a buffer to quench ER-a transcriptional activity in the absence of estrogen stimulation. However, a number of reports show that BRCA1 also inhibits estrogen-dependent transcription (Fan et al., 1999) . Co-transfection of wild-type BRCA1 with ER-a into breast and prostate cancer cells inhibited the ability of ER-a to transactivate luciferase reporter constructs containing estrogen responsive elements (Fan et al., 1999) . In addition, another study showed that overexpression of BRCA1 inhibited the induction of over 90% of estrogen-inducible genes (Xu et al., 2005) . This overexpression of BRCA1 in MCF-7 cells blunted estrogen-induced cell proliferation, an effect that was specific for the estrogen signaling pathway since BRCA1 failed to inhibit the proliferation of cells following IGF-I treatment (Xu et al., 2005) . The transcriptional activation and secretion of vascular endothelial growth factor (VEGF) protein, an estrogen-inducible gene in breast cells and a protein implicated in cancer growth and angiogenesis, was severely impaired in the presence of exogenous wild-type BRCA1 (Kawai et al., 2002) . Thus, BRCA1 may regulate the activity of VEGF through its ability to modulate ERa function. Signaling to extracellular signal-related kinase (ERK) in response to estradiol is also stunted in the presence of wild-type but not mutant BRCA1 (Razandi et al., 2004) . So BRCA1 acts to inhibit both ligand-independent and -dependent transcription through its association with ER-a.
The transcriptional repression activity of BRCA1 for ER-a is postulated to occur by the association of the amino-terminus of BRCA1 (aa 1-300) with the Cterminal activation function (AF-2) of ER-a (Fan et al., 1999) . Breast cancer-associated mutations of BRCA1 abolish or reduce its ability to inhibit ER-a activity (Fan et al., 2001) . The repression activity exerted by BRCA1 would appear to reside in the C-terminus since truncated BRCA1 proteins containing the ER-a interaction domain blocked the ability of full-length BRCA1 to inhibit ER-a transcriptional activity (Fan et al., 2001 ). This ligand-independent repression of ER-a transcription would appear to involve histone deacetylase activity since it was largely reversed by trichostatin A treatment (Zheng et al., 2001) . Another mechanism of BRCA1-mediated repression of ER-a transcription may be due to the ability of BRCA1 to downregulate levels of the transcriptional coactivator p300, which has also been shown to interact with the AF-2 domain of ER-a (Fan et al., 2002a) . Ectopic expression of p300 (or the functional homolog CBP) reversed BRCA1 inhibition of ER-a transcription (Fan et al., 2002a) . BRCA1 in this context may regulate the availability of p300 to compete for the AF-2 domain of ER-a. Cyclin D1 has also been reported to compete with BRCA1 for ER-a binding through a common hinge domain region and the binding of cyclin D1 resulted in the inhibition of BRCA1-mediated ER-a transcriptional repression by promoting ER-a recruitment to estrogen responsive elements (Wang et al., 2005) .
The cofactor of BRCA1, COBRA1 is a subunit of the human-negative elongation factor (NELF), binds to ER-a and negatively regulates ER-a activity (Aiyar et al., 2004) . However, COBRA1 does not inhibit the estrogen-dependent assembly of transcriptional regulatory complexes at estrogen-responsive promoters (even though COBRA1 and other NELF subunits are recruited to promoters following estrogen stimulation) but instead causes RNA polII to stall at the promoterproximal region (Aiyar et al., 2004) .
Another coregulator of BRCA1 transcription is MED1/TRAP220, which was shown to interact with the BRCT region of BRCA1, an interaction which was also abolished when cancer-associated point mutations were introduced into the BRCT region (Wada et al., 2004) . Both the BRCA1 transactivation function and BRCA1-mediated survival following DNA damage was reduced upon antisense knockdown of MED1/ TRAP220 (Ikeda et al., 2002) . MED1/TRAP220 is a key coactivator for many transcription factors most notably nuclear receptors and RNAi silencing experiments show that it is required for estrogen-dependent breast cell growth and ER-a-dependent transcription (Zhang et al., 2005) . It is likely therefore that the BRCA1-TRAP220 interaction is important in the modulation of ER-a transcriptional activity.
P53
The modulation of transcription factor activity by BRCA1 is best documented by its interaction with p53. BRCA1 (aa 224-500) was shown to interact with the C-terminus of p53 and in so doing alters the transcriptional activity of p53 . BRCA1 increased transcription from p53-responsive promoters such as p21 cip1/WAF1 and bax, whereas cancerassociated transactivation-deficient mutants of BRCA1 did not. Following this, another group reported that a region in the C-terminus of BRCA1 incorporating the second BRCT domain (aa 1760-1863) was also capable of interacting with p53 in vitro and was sufficient to stimulate p53-dependent transcription from the p21 cip1/ WAF1 promoter (Chai et al., 1999) . However, while BRCA1 stimulated p53-dependent transcription, it was noteworthy that even though a large number of p53-responsive genes are proapoptotic BRCA1 overexpression did not lead to the apoptosis in most of the cell lines investigated. BRCA1-stabilized p53 was found to specifically regulate the transcription of genes involved in DNA repair and growth arrest rather than proapoptotic genes (MacLachlan et al., 2002) . While DNA damage stabilized p53 and led to the transcription of multiple genes including apoptotic genes, BRCA1-stabilized p53 defaulted p53 target genes to DNA damage repair. The differential regulation of p53 transcription by BRCA1 towards growth arrest was also demonstrated in mouse embryonic fibroblasts where reintroduction of BRCA1 and p53 into double knockout cells resulted in markedly increased senescence compared to the reintroduction of p53 alone (Ongusaha et al., 2003) . BRCA1 also inhibited p53-mediated cell death in response to gamma-irradiation (Ongusaha et al., 2003) . The BRCA1-mediated promotion of p53 induced cell cycle arrest genes was also observed in mouse embryonic stem cells, where although the majority of p53 target genes remained unchanged following Brca1 knockout, the induction of 14-3-3s, a major G2/M checkpoint gene was severely attenuated following gamma-irradiation (Aprelikova et al., 2001) .
While BRCA1 participates in the stabilization of p53 in response to DNA damage and stimulates the activation of p53-dependent gene expression, p53 in turn acts to downregulate BRCA1 levels in a negative feedback loop (MacLachlan et al., 2000a) . p53 may also effect BRCA1 subcellular localization since BRCA1 is exported from the nucleus via a CRM1-and p53-dependent mechanism (Feng et al., 2004) . BRCA1 may promote the accumulation of p53 through its ability to regulate the levels of p14 ARF since BRCA1 cannot stabilize p53 in p14 ARF -deficient cells (Somasundaram et al., 1999) . Additionally, another mode of BRCA1 stabilization of p53 may occur through its role in facilitating p53 phosphorylation in response to DNA damage. BRCA1 (along with its heterodimer partner BARD1) has been shown to be required for the ability of ataxia telangiectasia-mutated (ATM) and ataxiatelangiectasia mutated and RAD3-related (ATR) to phosphorylate p53 on serine 15 in response to gammaand ultraviolet-irradiation, respectively (Fabbro et al., 2004) . This phosphorylation event is critical for G1/S arrest in response to gamma-irradiation through induction of p21 cip1/WAF1 . In summary, the interaction of BRCA1 with p53 results in the redirection of p53-mediated transactivation from proapoptotic targets to genes involved in DNA repair and/or cell cycle arrest.
STAT1
BRCA1 (aa 502-802) has been reported by several groups to interact with the C-terminus of the transcription factor STAT1 (Ouchi et al., 2000) . This interaction was shown to be important for the growth arrest following interferon gamma (IFNg) treatment, through the induction of p21 cip1/WAF1
, which contains an IFNg-responsive element in its promoter (Ouchi et al., 2000) . BRCA1 associates with and modulates the transcriptional activity of STAT1, an interaction which requires wild-type BRCA1 since the induction of p21 cip1/WAF1 by IFNg was abrogated in BRCA1 mutant HCC1937 cells (Ouchi et al., 2000) . Following this we identified a number of other transcriptional targets of BRCA1 by microarray analysis, many of which had been previously shown to be induced by interferons (Andrews et al., 2002) . The induction of some of these targets by BRCA1, such as IRF7, MxA, 2,5 OAS and ISG54 was synergistically enhanced with IFNg (not with type I interferons) and was accompanied by an induction of apoptosis. One of these transcriptional targets, interferon regulatory factor 7 (IRF7) is a key molecule in the amplification of the interferon cascade in response to viral infection suggesting that BRCA1 may play a transcriptional role in the innate immune response to viral infection (Marie et al., 1998) . Another downstream target of BRCA1 was 2,5 oligoadenylate synthase (2,5 OAS), which was shown to act as a mediator of apoptosis in a BRCA1 and IFNg-dependent manner (Mullan et al., 2005) . STAT1 itself was found to be upregulated in a BRCA1-dependent manner following inducible expression of BRCA1 in another microarray experiment (Welcsh et al., 2002) . Therefore, the interaction of BRCA1 with STAT1 and the requirement for BRCA1 in the induction of transcription following IFNg suggest yet another role for BRCA1, namely in the sensitization of breast (and probably other) cell types to the immunosurveillance and antiproliferative effects of IFNg.
c-Myc
It is worth noting that while most attention has focused on BRCA1 acting as a coactivator in association with proteins such as p53 and STAT1 it also plays an important role as a transcriptional corepressor. c-Myc is generally considered to act as a direct transcriptional activator (usually in association with Max) by binding to E-box motifs in the promoters of responsive genes. In a yeast two-hybrid screen c-Myc was identified as an BRCA1 interacting partner, an interaction which required the helix-loop-helix region of c-Myc, a region which is also involved in Myc-Max dimerization (Wang et al., 1998) . Two amino-terminal regions of BRCA1 (aa 175-303 and aa 443-511) were required for interaction with c-Myc (Wang et al., 1998) . BRCA1 was found to inhibit Myc-mediated transcription and reversed the transforming activity of c-Myc in association with other oncogenes such as Ras (Wang et al., 1998) . BRCA1 (aa 298-693) and (aa 1301-1863) was also found to interact with another Myc-interacting protein, Nmi (N-Myc-interacting protein) . Nmi is thought to function as an adaptor molecule, facilitating the formation of an Nmi-Myc-BRCA1 complex and Nmi when co-transfected with BRCA1 was shown to significantly inhibit c-Myc induced transcription of the human telomerase reverse transcriptase gene, human telomerase reverse transcriptase (hTERT) promoter . Cancer-associated mutations of BRCA1 failed to disrupt binding to c-Myc and Nmi, however, these mutations did abrogate BRCA1-c-Myc-mediated repression of telomerase, an event which, would be predicted to be highly carcinogenic. Although the amino-terminus of BRCA1 was required for c-Myc interaction, c-Myc transcriptional activity and suppression of TERT activity, the C-terminal was not (Xiong et al., 2003) . Cancer-associated C-terminal point or truncating mutations were still able to suppress TERT promoter-reporter activity while a full-length BRCA1 construct containing a tumor-associated RING domain mutation (T300G) could not (Xiong et al., 2003) . These data therefore suggest that both the BRCA1 aminoterminus and an intact RING domain are required for effective suppression of c-Myc transcription and subsequently TERT activity. Recently, we have shown that BRCA1, through its interaction with Myc, leads to the downregulation of a number of other transcriptional targets including psoriasin (S100A7) and that a fully functional BRCA1 and c-Myc were both required for this repression ). It appears therefore that BRCA1 functions as a repressor in association with c-Myc, and BRCA1 may therefore function to curb the oncogenic potential of c-Myc.
CtIP
CtIP was shown by yeast two-hybrid to interact with the C-terminal region (aa 1602-1863) of BRCA1 (Wong et al., 1998; Yu et al., 1998) . This interaction required full-length BRCA1 since deletion of the last 11 aa of BRCA1 abrogated this association suggesting that it required functional BRCT domains. CtIP was first identified as an interactor with the transcriptional repressor CtBP indicating that it may play a role in transcriptional regulation (Schaeper et al., 1998) . The association of BRCA1 with CtIP is abrogated following DNA damage indicating that BRCA1 and/or CtIP phosphorylation may disrupt this interaction (Li et al., 1999) . A potential model was proposed suggesting that ATM phosphorylation of BRCA1 and its associated corepressor CtIP following DNA damage led to the dissociation of BRCA1 and CtIP, resulting in the BRCA1-mediated upregulation of GADD45 . The dissociation of CtIP and BRCA1 was shown to be critical for the induction of GADD45 following ionizing radiation . CtIP was shown to be a phosphorylation target for ATM following DNA damage on serines 664 and 745 and mutation of these sites resulted in the abrogation of CtIP-BRCA1 dissociation and GADD45 induction . In contrast it was also reported that CtIP was found in a complex associating with BRCA1 and BARD1 and that this complex was stable following DNA damage (Yu and Baer, 2000; Wu-Baer and Baer, 2001) . The discrepancies between these reports relating to the significance of CtIP phosphorylation for BRCA1 dissociation remain to be resolved but may be explained by potential experimental artefacts caused by the use of different antibodies and cell lines for co-immunoprecipitation studies. Whatever the significance of BRCA1-CtIP dissociation for transcription, the current understanding is that the BRCA1-CtIP interaction has an important role to play in the DNA damagedependent induction of genes such as GADD45.
ZBRK1
Another protein implicated in BRCA1 transcriptional regulation of GADD45 is the KRAB eight zinc-finger protein, ZBRK1. ZBRK1 is a transcriptional corepressor and was shown to bind to a specific sequence within GADD45 intron 3 after complexing with BRCA1 . In this context ZBRK1 appeared to repress GADD45 transcription in a BRCA1-dependent manner, and the GADD45 promoter is possibly de-repressed following BRCA1 activation by stress or damage stimuli . ZBRK1 has two repression domains with the CTD acting in a BRCA1-, histone deacetylase-and sequence-specific manner (Tan et al., 2004b) . This C-terminal repression domain was shown to be functionally distinct from the aminoterminal KRAB repression domain and includes elements that modulate its DNA-binding activity (Tan et al., 2004b) . The binding of BRCA1 to this C-terminal repression domain (CTRD) of ZBRK1 was found to be necessary but not sufficient for CTRD repression activity since BRCA1-binding, repression-defective ZBRK1 mutants could be generated (Tan et al., 2004a) . In addition, an alternative BRCA1-independent mode of Gadd45a induction following DNA damage has been proposed by another group (Yun and Lee, 2003) . They identified a region of ZBRK1 (between the KRAB domain and zinc fingers) which resulted in the ubiquitylation and degradation of ZBRK1 and subsequent induction of Gadd45a following DNA damage (Yun and Lee, 2003) .
While GADD45 is best known as a p53-regulated growth arrest and DNA-damage-inducible gene, it is also regulated in a p53-independent manner. This p53-independent induction is dependent on a functional BRCA1 transactivation domain, and by 5 0 -deletion analysis was shown to map to the À121 to À75 region of the GADD45 promoter (Jin et al., 2000) . BRCA1 was also found to physically associate with transcription factors Oct-1 and NF-YA, which directly bind to the OCT-1 and CAAT motifs in the GADD45 promoter (Fan et al., 2002b) . Mutation of either motif disrupted BRCA1 binding to the GADD45 promoter (Fan et al., 2002b) . Taken together these reports suggest that BRCA1 coordinates the p53-independent induction of GADD45 following DNA damage by derepression of ZBRK1 and stimulation of transcription through its association with specific transcription factors. A schematic outlining the interactions of BRCA1 with transcription factors is outlined in Figure 1 . The specific role of BRCA1 in the regulation of GADD45 following DNA damage is shown in Figure 2 .
BRCA1 and cell cycle control
BRCA1 has been shown to be an important determinant of cellular responses to chemotherapy and there is considerable evidence to suggest that it shows promise as a predictive marker. Most of the preclinical studies performed on BRCA1 have focused on the role of BRCA1 in DNA damage repair and in particular on its role in homologous recombination repair (HRR) and non-homologous end-joining (NHEJ) repair of DNA 
GADD45
CtIP Figure 2 Proposed mechanism of BRCA1 induced of transcription of GADD45 in a p53-independent manner. The association of BRCA1 with CtIP is disrupted following DNA damage by multiple phosphorylations of BRCA1 (including serines 988, 1387, 1423, 1457, 1524) and at least two serines on CtIP (serines 664 and 745). Phosphorylated BRCA1 interacts with ZBRK1 which is constitutively bound to a GADD45 intron 3 region leading to the derepression of ZBRK1-mediated inhibition of GADD45. BRCA1 also binds the sequence specific transcription factors Oct-1 and NF-YA to co-activate GADD45 transcription from another region in the GADD45 promoter ( represents DNA damage).
double-strand breaks (Moynahan et al., 1999 (Moynahan et al., , 2001 Zhong et al., 2002) . BRCA1 has also been consistently linked to cell cycle control and elicits cell cycle arrest at several phases of the cell cycle, which would appear to complement its role in DNA damage repair processes, allowing adequate time for DNA repair to occur. In this section of the review we will discuss the role of BRCA1 in cell cycle control and in particular how its role in transcriptional regulation underpins its ability to regulate specific stress activated cell cycle checkpoints.
The phosphorylation status of BRCA1 has already been shown to have an impact on its role in transcriptional regulation. A number of studies have also demonstrated that phosphorylation of BRCA1 is also required to activate specific DNA damage induced checkpoints such as the intra S-phase checkpoint. For example, BRCA1 is phosphorylated on serine 1387 by ATM, and this phosphorylation event is required for the activation of the intra-S phase checkpoint in response to DNA damage (Xu et al., 2002) . In addition, the phosphorylation of BRCA1 on serine 1423 has been shown to be important for G2/M cell cycle arrest (Xu et al., 2001) . Evidence is now beginning to accumulate to suggest that the phosphorylation status of BRCA1 may affect DNA damage-induced checkpoint activation through modulation of specific downstream target genes.
G1/S checkpoint BRCA1 has been shown to activate p21 cip1/WAF1 , a feature that may contribute to arrest at the G1/S boundary. Indeed, BRCA1 could not prevent S phase progression in p21 cip1/WAF1À/À cells and tumor-associated mutants of BRCA1 are both deficient in the transactivation of p21 cip1/WAF1 and cell cycle inhibition (Somasundaram et al., 1997) .
A number of other reports have supported a role for BRCA1 in the regulation of p21 cip1/WAF1 and activation of the G1/S phase checkpoint. The association of CtIP with the BRCT domains of BRCA1 has been shown to involved in the regulation p21 cip1/WAF1 and the expression of exogenous CtIP and CtBP abolished the ability of BRCA1 to transactivate p21 cip1/WAF1 in response to DNA damage (Li et al., 1999) . The activation of p21 cip1/WAF1 transcription correlated with BRCA1 phosphorylation, further suggesting a link between BRCA1 phosphorylation status and its role in transcriptional regulation (Li et al., 1999) . BRCA1 has also been reported to regulate p21 cip1/WAF1 transactivation and G1/S arrest in an indirect manner involving p53. BRCA1 in association with its binding partner BARD1, have both been shown to be required for the phosphorylation of p53 on serine 15 and subsequent G1/S arrest following ionizing radiation-induced DNA damage (Fabbro et al., 2004) . BRCA1 or BARD1 depletion by siRNA led to compromised p21 cip1/WAF1 induction and abrogation of G1/S arrest. Furthermore, phosphorylation of p53 on serine 15 was dependent on ATM/ATR-mediated phosphorylation of BRCA1 (Fabbro et al., 2004) . Taken together these reports all suggest that p21 cip1/WAF1 is a key downstream transcriptional target of BRCA1 and that the phosphorylation status of BRCA1 is a requisite event for G1/S arrest. BRCA1 has also been postulated to have a direct transcriptional role in the regulation of p27 kip1 resulting in S-phase arrest (Williamson et al., 2002) . Indeed, one of the characteristics of BRCA1 mutant breast cancers is the associated negative staining for p27 kip1 (Chappuis et al., 2000) . However, work from our group suggests that the regulation of p27 kip1 by BRCA1 may be through a post-transcriptional mechanism since altering BRCA1 expression using BRCA1 siRNA experiments or the reconstitution of BRCA1 back into BRCA1 mutant HCC1937 cells led to changes in p27 kip1 protein but not p27 kip1 mRNA levels (unpublished observations).
Intra S-phase checkpoint
Compared to the G1/S checkpoint the role of BRCA1 and transcription in the intra-S-phase/replication checkpoint is somewhat more ambiguous. As mentioned already ATM phosphorylates BRCA1 on serine 1387 and this is essential for intra S-phase checkpoint activation (Xu et al., 2002) . Both ATM and BRCA1 have been shown to be required for S-and G2/M-phase checkpoints (Xu et al., 2001) . The specificity of BRCA1 phosphorylation events and their importance in cell cycle control is perhaps best demonstrated by the fact that mutation of serine 1423 on BRCA1 (also an ATM target site) abrogates G2/M arrest but not S phase arrest in response to ionizing radiation (Xu et al., 2001) . From a transcriptional perspective it is possible that through the transcriptional upregulation of p21 cip1/WAF1 BRCA1 may interfere with S phase progression. p21 cip1/WAF1 has previously been shown to perform this role by inhibiting replicative DNA synthesis, an event which was antagonized by cyclin E-cdk2 and cyclin A-cdk2 activities (Ogryzko et al., 1997) .
G2/M checkpoint BRCA1 has also been shown to be a transcriptional regulator of several genes associated with the regulation of the G2/M checkpoint. BRCA1 has been reported to transcriptionally repress CyclinB, the cyclin responsible for activating cdc2 kinase and mitotic entry (MacLachlan et al., 2000b) . BRCA1 also transcriptionally regulates the chaperone protein 14-3-3s, which targets cdc25C and sequesters it in the cytoplasm following DNA damage to prevent it from activating the cyclinBcdc2 kinase complex (Yarden et al., 2002) . Indeed similar to 14-3-3s, BRCA1 mutant cells were shown to be unable to elicit a G2/M arrest in response to ionizing radiation (Aprelikova et al., 2001) . BRCA1 also stimulates the transcription of the wee-1 kinase leading to the inhibitory phosphorylation of cdc2 and subsequent inhibition of cyclinB-cdc2 kinase (Yarden et al., 2002) . It also inhibits the transcription of PLK1, a kinase required for G2 to M transition, in response to ionizing radiation (Ree et al., 2003) . However, the most compelling evidence for BRCA1 transcriptional regulation and G2/M cell cycle arrest comes from its regulation of GADD45. GADD45 is known to regulate the CyclinB-cdc2 complex leading to inhibition of kinase activity by the sequestration of cdc2 ). An overview of the roles of BRCA1 transcriptional targets in cell cycle control is shown in Figure 3 .
Mitotic checkpoint
As well as cell cycle regulation in response to DNA damage we have previously shown that BRCA1 may also regulate the spindle checkpoint in response to microtubule damage, sensitizing breast cancer cells to the spindle poisons Taxol and Vincristine (Mullan et al., 2001; Quinn et al., 2003) . It is not known at present how BRCA1 enhances spindle arrest in response to these drugs but this may be due in part to its association with and subsequent activation of MEKK3 following microtubule damage (Gilmore et al., 2004) . We previously demonstrated that inducible expression of GADD45 also activated the G2/M checkpoint in response to microtubule agents, suggesting that BRCA1-mediated transactivation of GADD45 may be important in the regulation of the mitotic checkpoint (Mullan et al., 2001) . BRCA1 has also been demonstrated to be involved in the transcriptional regulation of MAD2, a key component of the spindle assembly checkpoint through its ability to interact with and control the activity of the cdc20/Anaphase Promoting Complex/C (APC/C) (Wang et al., 2004) . The transcriptional regulation of MAD2 by Brca1 was thought to be due to the ability of Brca1 to bind to and interact with the transcription factor Oct1. It is clear, however, that much more work needs to be carried out to gain a better understanding of how BRCA1 may regulate the mitotic checkpoint.
Conclusion and perspectives
It is clear that BRCA1 represents a multifunctional protein that can suppress tumor formation through the regulation of a number of important cellular mechanisms. Although BRCA1 is generally considered a DNA repair protein, first and foremost, it is clear that its ability to function as a transcriptional coactivator or corepressor represents a critical component of its overall role in tumor suppression. Furthermore, the diverse roles associated with BRCA1 need not be mutually exclusive. Indeed, we are beginning to see a picture emerge where BRCA1 acts as a conductor orchestrating a variety of key signaling events in normal replicating cells and following DNA damage. Following DNA damage it is clear that BRCA1 is actively recruited to the sites of damage to facilitate the actual repair process while simultaneously modulating key transcriptional programs that ensure cell survival through the activation of cell cycle checkpoints and the inhibition of apoptosis. One of the interesting areas for future work in this field relate to the effect of specific post- 
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Figure 3 An overview of BRCA1 transcriptional regulation and cell cycle control in response to DNA damage. BRCA1 through a number of p53-dependent and -independent mechanisms can stimulate the transcription of p21 WAF1/cip1 leading to G1/S and an intra-Sphase arrest. It stimulates the transcription of a number of G2/M checkpoint regulatory genes such as GADD45, wee1 or 14-3-3s which inhibit the cdc2-cyclinB mitotic kinase by the sequestration of cdc2, the inhibitory phosphorylation of cdc2, or by the sequestration of cdc25C, respectively. In addition it can also inhibit the transcription of cyclinB as well as PLK1 following DNA damage. All of these BRCA1 transcription regulation events contribute to stalling of cdc2-cyclinB kinase activity and the prevention of mitotic entry.
translational modification of BRCA1 on its role in transcriptional regulation. In addition the role of BRCA1 as a potential scaffold to enhance posttranscriptional modification of key transcription factors merits further investigation. Finally, it is also interesting to speculate that the only known enzymatic activity associated with BRCA1, namely its E3 ligase activity may also represent a common mechanism through which it regulates the activity of specific transcriptional complexes.
